Sanhuang pills for wet age-related macular degeneration
Part of Cancer, Eyes & vision clinical trials.
This trial tests whether a traditional Chinese medicine pill, Sanhuang Jingshiming, can help people with wet age-related macular degeneration (a condition where abnormal blood vessels leak fluid in the eye). It aims to see if the pill improves vision and is safe compared to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have been diagnosed with wet age-related macular degeneration (nAMD) in at least one eye, and the disease is active (causing new blood vessel growth or leakage).
- Your vision in the study eye is between 25 and 78 letters on a standard eye chart (roughly 20/320 to 20/25).
- You have not had anti-VEGF injections (like Lucentis) in the study eye within the last 4 months.
- You have not had other eye treatments (like laser or surgery) in the study eye within the last 6 months.
- You are willing to follow the trial procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral tablet for people with wet age-related macular degeneration. It may offer a new way to treat the condition without frequent eye injections.
This trial tests an investigational medicine (QA108) for people with intermediate age-related macular degeneration (AMD). It aims to slow or prevent progression of the disease by treating the deposits (drusen) in the center of the retina.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
This study tests an eye drop solution designed to treat wet age-related macular degeneration (AMD), a condition that causes blurry vision due to abnormal blood vessel growth. The treatment aims to reduce fluid and improve vision without the need for frequent eye injections.
Hear when a new AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.